ATM clinical trials
25 active trials name this biomarker in their eligibility criteria (recorded in the registry as “ATM Gene”) . Describe your situation to see which ones you may be eligible for.
- High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)
- Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
- A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
- Combination Therapy in Cancers With Mutations in DNA Repair Genes
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
- Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- The Cancer of the Pancreas Screening-5 CAPS5)Study
- A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
- Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
- Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Pilot Study of Pancreatic Cancer Screening
- Pancreatic Cancer Screening for At-risk Individuals
- A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
- Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
- Pancreatic Cancer Early Detection Consortium
- Pancreas Registry and High Risk Registry
- Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
- [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
- Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
- Prospective Familial Registry for Pancreas Research
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “ATM Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.